Zoetis Inc. is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers. Its livestock products include Ceftiofur injectable line, Draxxin, Spectramast, Bovi-Shield line, Rispoval line, Suvaxyn/Fostera, Embrex devices and Lutalyse. Its companion animal products include Clavamox/Synulox, Convenia, ProHeart, Revolution/Stronghold, Apoquel, Cerenia and Rimadyl.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Veterinary Drugs
- Sub-Industry: Pharmaceuticals
- Symbol: NYSE:ZTS
- CUSIP: 98978V10
- Web: www.zoetis.com
Capitalization:- Market Cap: $29.71 billion
- Outstanding Shares: 489,111,000
Average Prices:- 50 Day Moving Avg: $62.00
- 200 Day Moving Avg: $58.20
- 52 Week Range: $46.86 - $63.85
P/E:- Trailing P/E Ratio: 34.43
- Foreward P/E Ratio: 22.67
- P/E Growth: 1.93
Sales & Book Value:- Annual Revenue: $5.02 billion
- Price / Sales: 5.92
- Book Value: $3.50 per share
- Price / Book: 17.36
Dividend:- Annual Dividend: $0.42
- Dividend Yield: 0.7%
Profitability:- EBIDTA: $1.73 billion
- Net Margins: 17.50%
- Return on Equity: 62.49%
- Return on Assets: 13.14%
Debt:- Debt-to-Equity Ratio: 2.13%
- Current Ratio: 2.01%
- Quick Ratio: 1.17%
Misc:- Average Volume: 2.47 million shs.
- Beta: 1.02
- Short Ratio: 3.82
Frequently Asked Questions for Zoetis (NYSE:ZTS)
What is Zoetis' stock symbol?
Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."
How often does Zoetis pay dividends? What is the dividend yield for Zoetis?
Zoetis declared a quarterly dividend on Friday, May 12th. Shareholders of record on Thursday, June 15th will be paid a dividend of $0.105 per share on Friday, September 1st. This represents a $0.42 dividend on an annualized basis and a yield of 0.69%. The ex-dividend date is Tuesday, June 13th. View Zoetis' Dividend History.
How were Zoetis' earnings last quarter?
Zoetis Inc. (NYSE:ZTS) issued its quarterly earnings data on Tuesday, August, 8th. The company reported $0.53 EPS for the quarter, missing analysts' consensus estimates of $0.53 by $0.00. The company earned $1.27 billion during the quarter, compared to the consensus estimate of $1.27 billion. Zoetis had a net margin of 17.50% and a return on equity of 62.49%. Zoetis's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.49 EPS. View Zoetis' Earnings History.
When will Zoetis make its next earnings announcement?
Where is Zoetis' stock going? Where will Zoetis' stock price be in 2017?
17 equities research analysts have issued twelve-month price targets for Zoetis' stock. Their predictions range from $35.00 to $77.00. On average, they expect Zoetis' stock price to reach $64.41 in the next year. View Analyst Ratings for Zoetis.
What are analysts saying about Zoetis stock?
Here are some recent quotes from research analysts about Zoetis stock:
- 1. According to Zacks Investment Research, "Zoetis’ growth in revenues is being driven by sales of companion animal products such as Simparica, Apoquel and Cytopoint while the livestock portfolio was driven by growth in swine, cattle and fish across the international markets. Zoetis’ expects to see stronger growth from its companion animal portfolio in 2017 driven by Apoquel and Cytopoint, further penetration of Simparica, and ongoing uptake of new vaccines. Favorable market conditions contributed to swine performance in China as well as cattle product sales in Brazil. Shares of Zoetis have outperformed the industry in 2017 so far. However, disease outbreak among animals is a material cause of concern for Zoetis’ livestock products. Zoetis faces stiff competition from companies like Merck Animal Health (the animal health division of Merck), Elanco (the animal health division of Eli Lilly among others. " (7/4/2017)
- 2. Guggenheim analysts commented, "We are raising our PT for ZTS shares after a 4Q beat and a lower than expected FX headwind for '17. The increase in our PT is driven by multiple expansion. We arrive at our new PT by using a DCF analysis. ZTS's solid execution this quarter increases our confidence that it can exceed consensus expectations for '17+ and sustain its 21x forward P/E multiple. Upward earnings revisions could come from margin expansion, M&A, and launches. Therefore, the sell-off today, which we think is motivated by profit taking, is overdone, in our view. We believe the weakness (ZTS down 3% vs. S&P down 0.14%) presents a good buying opportunity for the stock." (2/16/2017)
Who are some of Zoetis' key competitors?
Some companies that are related to Zoetis include Stryker Corporation (SYK), Aetna (AET), Anthem (ANTM), Regeneron Pharmaceuticals (REGN), Becton, Dickinson and Company (BDX), Takeda Pharmaceutical (TKPYY), Vertex Pharmaceuticals Incorporated (VRTX), Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Humana (HUM), Express Scripts Holding Company (ESRX), Baxter International (BAX), McKesson Corporation (MCK), Alexion Pharmaceuticals (ALXN), Actelion (ALIOF), Fresenius Medical Care Corporation (FMS), HCA Holdings (HCA) and Illumina (ILMN).
Who are Zoetis' key executives?
Zoetis' management team includes the folowing people:
- Juan Ramon Alaix, Chief Executive Officer, Director
- Glenn David, Chief Financial Officer, Executive Vice President
- Roxanne Lagano, Chief Human Resource Officer, Executive Vice President
- Andrew Fenton, Executive Vice President, Chief Information Officer
- Heidi C. Chen, Executive Vice President, General Counsel, Corporate Secretary
- Alejandro Bernal, Executive Vice President, Group President - Strategy, Commercial and Business Development
- Catherine A. Knupp, Executive Vice President, President - Research and Development
- Clinton A. Lewis Jr., Executive Vice President, President - International Operations
- Kristin C. Peck, Executive Vice President, President - U.S. Operations
- Roman Trawicki, Executive Vice President, President of Global Manufacturing and Supply
Who owns Zoetis stock?
Zoetis' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.64%), Vanguard Group Inc. (6.86%), State Street Corp (4.22%), State Farm Mutual Automobile Insurance Co. (3.90%), Alliancebernstein L.P. (2.11%) and Independent Franchise Partners LLP (1.76%). Company insiders that own Zoetis stock include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck, Michael B Mccallister, Pershing Square Capital Manage and Roxanne Lagano. View Institutional Ownership Trends for Zoetis.
Who sold Zoetis stock? Who is selling Zoetis stock?
Zoetis' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Winslow Capital Management LLC, Independent Franchise Partners LLP, Lazard Asset Management LLC, Marshall Wace North America L.P., California Public Employees Retirement System, First Eagle Investment Management LLC and Eaton Vance Management. Company insiders that have sold Zoetis stock in the last year include Andrew Fenton, Catherine A Knupp, Heidi C Chen, Kristin C Peck and Roxanne Lagano. View Insider Buying and Selling for Zoetis.
Who bought Zoetis stock? Who is buying Zoetis stock?
Zoetis' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Alliancebernstein L.P., BlackRock Inc., AJO LP, Harbour Capital Advisors LLC, Thrivent Financial For Lutherans, Northwestern Mutual Investment Management Company LLC and Vanguard Group Inc.. View Insider Buying and Selling for Zoetis.
How do I buy Zoetis stock?
Shares of Zoetis can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Zoetis' stock price today?
One share of Zoetis stock can currently be purchased for approximately $60.75.
MarketBeat Community Rating for Zoetis (NYSE ZTS)MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Zoetis (NYSE:ZTS) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 4 Hold Ratings, 12 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.65) |
| Consensus Price Target: | $64.41 (6.03% upside) |
Analysts' Ratings History for Zoetis (NYSE:ZTS)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/14/2017 | Cantor Fitzgerald | Set Price Target | Buy | $75.00 | Low |  |
| 8/7/2017 | Goldman Sachs Group, Inc. (The) | Reiterated Rating | Neutral -> Neutral | $62.00 | Low | |
| 7/25/2017 | Deutsche Bank AG | Downgrade | Buy -> Hold | $65.00 | High | |
| 7/21/2017 | Stifel Nicolaus | Reiterated Rating | Buy | $65.00 | Low | |
| 7/17/2017 | Cowen and Company | Set Price Target | Buy | $70.00 | Low | |
| 6/20/2017 | Hilliard Lyons | Initiated Coverage | Buy | $77.00 | Low | |
| 6/13/2017 | BMO Capital Markets | Downgrade | Outperform -> Market Perform | $64.00 -> $65.00 | Low | |
| 5/30/2017 | Argus | Reiterated Rating | Buy | $60.00 -> $69.00 | Low | |
| 5/26/2017 | CL King | Initiated Coverage | Buy -> Buy | $71.00 | Low | |
| 5/24/2017 | Credit Suisse Group | Boost Price Target | Outperform | $61.00 -> $67.00 | Low | |
| 5/9/2017 | Jefferies Group LLC | Boost Price Target | Buy | $65.00 -> $70.00 | Low | |
| 3/15/2017 | Craig Hallum | Initiated Coverage | Buy | $65.00 | Low | |
| 2/16/2017 | Guggenheim | Boost Price Target | Buy | $60.00 -> $65.00 | N/A | |
| 2/16/2017 | Off Wall Street | Reiterated Rating | Strong Sell | $35.00 | N/A | |
| 12/15/2016 | Piper Jaffray Companies | Reiterated Rating | Overweight | $61.00 | N/A | |
| 11/3/2016 | J P Morgan Chase & Co | Reiterated Rating | Hold | $53.00 | N/A | |
| 9/29/2016 | Bank of America Corporation | Initiated Coverage | Buy | $60.00 | N/A | |
| 8/4/2016 | Citigroup Inc. | Boost Price Target | Neutral | $50.00 -> $53.00 | N/A | |
| 8/4/2016 | Barclays PLC | Boost Price Target | Equal Weight | $45.00 -> $49.00 | N/A | |
| 1/8/2016 | Cleveland Research | Initiated Coverage | Buy | | N/A | |
(Data available from 8/18/2015 forward)
Earnings History for Zoetis (NYSE:ZTS)Earnings History by Quarter for Zoetis (NYSE ZTS)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/31/2017 | | $0.62 | | | | | N/A | |
| 8/8/2017 | Q2 2017 | $0.53 | $0.53 | $1.27 billion | $1.27 billion | View | Listen | |
| 5/4/2017 | Q1 2017 | $0.48 | $0.53 | $1.20 billion | $1.23 billion | View | Listen | |
| 2/16/2017 | Q416 | $0.45 | $0.47 | $1.28 billion | $1.30 billion | View | N/A | |
| 11/2/2016 | Q316 | $0.46 | $0.52 | $1.22 billion | $1.20 billion | View | N/A | |
| 8/3/2016 | Q216 | $0.44 | $0.49 | $1.17 billion | $1.20 billion | View | N/A | |
| 5/4/2016 | Q116 | $0.41 | $0.48 | $1.10 billion | $1.20 billion | View | N/A | |
| 2/16/2016 | Q415 | $0.39 | $0.43 | $1.25 billion | $1.30 billion | View | Listen | |
| 11/3/2015 | Q315 | $0.40 | $0.50 | $1.18 billion | $1.20 billion | View | N/A | |
| 8/4/2015 | Q215 | $0.38 | $0.43 | $1.12 billion | $1.20 billion | View | N/A | |
| 5/5/2015 | Q115 | $0.37 | $0.41 | $1.11 billion | $1.10 billion | View | N/A | |
| 2/11/2015 | Q414 | $0.36 | $0.40 | $1.27 billion | $1.30 billion | View | N/A | |
| 11/4/2014 | Q314 | $0.37 | $0.41 | $1.16 billion | $1.20 billion | View | N/A | |
| 5/6/2014 | Q114 | $0.37 | $0.38 | $1.13 billion | $1.10 billion | View | N/A | |
| 2/11/2014 | Q413 | $0.34 | $0.36 | $1.21 billion | $1.25 billion | View | N/A | |
| 11/5/2013 | Q313 | $0.34 | $0.34 | $1.07 billion | $1.10 billion | View | N/A | |
| 8/6/2013 | Q2 2013 | $0.36 | $0.36 | $1.13 billion | $1.11 billion | View | N/A | |
| 4/30/2013 | Q1 2013 | $0.27 | $0.36 | $1.24 billion | $1.09 billion | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Zoetis (NYSE:ZTS)2017 EPS Consensus Estimate: $2.26
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 2 | $0.47 | $0.49 | $0.48 |
| Q2 2017 | 1 | $0.50 | $0.50 | $0.50 |
| Q3 2017 | 1 | $0.62 | $0.62 | $0.62 |
| Q4 2017 | 1 | $0.66 | $0.66 | $0.66 |
(Data provided by Zacks Investment Research)
Current Dividend Information for Zoetis (NYSE:ZTS)| Next Dividend: | 9/1/2017 |
| Annual Dividend: | $0.42 |
| Dividend Yield: | 0.69% |
| Dividend Growth: | 24.90% (3 Year Average) |
| Payout Ratio: | 23.73% (Trailing 12 Months of Earnings)
17.95% (Based on This Year's Estimates)
15.67% (Based on Next Year's Estimates)
|
| Track Record: | 3 Years of Consecutive Dividend Growth |
Dividend History by Quarter for Zoetis (NYSE ZTS)| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/12/2017 | quarterly | $0.11 | 0.7% | 6/13/2017 | 6/15/2017 | 9/1/2017 |
| 2/15/2017 | quarterly | $0.11 | 0.76% | 4/4/2017 | 4/6/2017 | 6/1/2017 |
| 12/6/2016 | quarterly | $0.11 | 0.82% | 1/18/2017 | 1/20/2017 | 3/1/2017 |
| 10/7/2016 | quarterly | $0.10 | 0.73% | 11/1/2016 | 11/3/2016 | 12/1/2016 |
| 5/13/2016 | quarterly | $0.10 | 0.82% | 6/28/2016 | 6/30/2016 | 8/30/2016 |
| 2/22/2016 | quarterly | $0.10 | 0.89% | 4/5/2016 | 4/7/2016 | 6/1/2016 |
| 12/17/2015 | quarterly | $0.10 | 0.81% | 1/19/2016 | 1/21/2016 | 3/1/2016 |
| 10/2/2015 | quarterly | $0.08 | 0.77% | 11/3/2015 | 11/5/2015 | 12/1/2015 |
| 7/22/2015 | quarterly | $0.08 | 0.66% | 8/11/2015 | 8/13/2015 | 9/1/2015 |
| 3/2/2015 | quarterly | $0.08 | 0.7% | 4/7/2015 | 4/9/2015 | 6/2/2015 |
| 12/18/2014 | quarterly | $0.08 | 0.77% | 1/20/2015 | 1/22/2015 | 3/3/2015 |
| 10/2/2014 | quarterly | $0.07 | 0.76% | 11/3/2014 | 11/5/2014 | 12/2/2014 |
| 7/31/2014 | quarterly | $0.07 | 0.88% | 8/18/2014 | 8/20/2014 | 9/2/2014 |
| 3/26/2014 | quarterly | $0.07 | 0.98% | 4/23/2014 | 4/27/2014 | 6/2/2014 |
| 12/19/2013 | quarterly | $0.07 | 0.89% | 1/28/2014 | 1/30/2014 | 3/4/2014 |
| 9/12/2013 | quarterly | $0.07 | 0.84% | 10/30/2013 | 11/1/2013 | 12/2/2013 |
| 6/20/2013 | quarterly | $0.07 | | | 8/1/2013 | 9/2/2013 |
| 3/29/2013 | special | $0.07 | | 4/29/2013 | 5/1/2013 | 6/6/2013 |
| 3/28/2013 | quarterly | $0.07 | | | 5/1/2013 | 6/6/2013 |
(Data available from 1/1/2013 forward)
Insider Trading and Institutional Ownership History for Zoetis (NYSE:ZTS)Insider Ownership Percentage: 0.31%
Institutional Ownership Percentage: 92.70%
Insider Trades by Quarter for Zoetis (NYSE:ZTS)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/12/2017 | Catherine A Knupp | Insider | Sell | 5,785 | $60.16 | $348,025.60 | |
| 11/22/2016 | Kristin C Peck | Insider | Sell | 10,092 | $49.55 | $500,058.60 | |
| 11/8/2016 | Roxanne Lagano | Insider | Sell | 9,797 | $50.43 | $494,062.71 | |
| 9/6/2016 | Michael B Mccallister | Director | Buy | 2,000 | $51.34 | $102,680.00 | |
| 9/2/2016 | Andrew Fenton | Insider | Sell | 13,870 | $51.25 | $710,837.50 | |
| 9/1/2016 | Heidi C Chen | Insider | Sell | 32,097 | $50.98 | $1,636,305.06 | |
| 5/9/2016 | Pershing Square Capital Manage | Director | Sell | 16,850,000 | $46.55 | $784,367,500.00 | |
| 8/8/2013 | Michael Mccallister | Director | Buy | 7,000 | $31.35 | $219,450.00 | |
| 2/6/2013 | Frank A Damelio | Director | Buy | 5,000 | $26.00 | $130,000.00 | |
| 2/6/2013 | Sandra J Beaty | EVP | Buy | 2,000 | $26.00 | $52,000.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Zoetis (NYSE:ZTS)
Latest Headlines for Zoetis (NYSE:ZTS)
| Source: |
|
| Date | Headline |
|---|
 | Zoetis (ZTS): Clavamox Chewable antibiotic Study Success Underscores Positive Thesis - Cantor - StreetInsider.com
www.streetinsider.com - August 15 at 8:42 AM |
 | Zoetis Inc. (NYSE:ZTS) PT Set at $75.00 by Cantor Fitzgerald
www.americanbankingnews.com - August 14 at 3:34 PM |
| FY2017 Earnings Forecast for Zoetis Inc. Issued By Cantor Fitzgerald (NYSE:ZTS)
www.americanbankingnews.com - August 14 at 3:52 AM |
 | See what the IHS Markit Score report has to say about Zoetis Inc.
finance.yahoo.com - August 11 at 9:24 AM |
| FY2017 Earnings Forecast for Zoetis Inc. (NYSE:ZTS) Issued By Gabelli
www.americanbankingnews.com - August 10 at 12:10 PM |
| Brokers Issue Forecasts for Zoetis Inc.'s FY2017 Earnings (NYSE:ZTS)
www.americanbankingnews.com - August 10 at 12:10 PM |
| Edited Transcript of ZTS earnings conference call or presentation 8-Aug-17 12:30pm GMT
finance.yahoo.com - August 10 at 1:38 AM |
| Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View - Yahoo Finance
finance.yahoo.com - August 9 at 8:37 PM |
 | Zoetis (ZTS) Beats on Q2 Earnings & Sales, Ups 2017 View - Nasdaq
www.nasdaq.com - August 9 at 3:34 PM |
| UPDATE: Goldman Sachs Reinstates Zoetis Inc. (ZTS) at Neutral - StreetInsider.com
www.streetinsider.com - August 9 at 3:34 PM |
 | Zoetis (ZTS) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 9:31 AM |
| Zoetis Inc. (ZTS) Announces Earnings Results, Hits Estimates
www.americanbankingnews.com - August 8 at 9:42 AM |
| Zoetis, Inc. – Value Analysis (NYSE:ZTS) : August 7, 2017
finance.yahoo.com - August 8 at 8:34 AM |
| Zoetis Announces Second Quarter 2017 Results
finance.yahoo.com - August 8 at 8:34 AM |
| Zoetis meets 2Q profit forecasts
finance.yahoo.com - August 8 at 8:34 AM |
| Zoetis (ZTS) Q2 Earnings In-line, Sales Beat; 2017 View Up
finance.yahoo.com - August 8 at 8:34 AM |
 | Should You Buy Zoetis (ZTS) Ahead of Earnings?
www.zacks.com - August 7 at 8:52 AM |
| Zoetis Inc. (ZTS) Expected to Announce Quarterly Sales of $1.25 Billion
www.americanbankingnews.com - August 6 at 9:14 AM |
| Zoetis Appoints Dr. Linda Rhodes to Board of Directors
finance.yahoo.com - August 4 at 10:20 AM |
| $0.53 EPS Expected for Zoetis Inc. (ZTS) This Quarter
www.americanbankingnews.com - August 4 at 8:02 AM |
| ETFs with exposure to Zoetis, Inc. : August 1, 2017
finance.yahoo.com - August 2 at 9:01 AM |
| Zoetis Inc. (NYSE:ZTS) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - August 1 at 7:16 AM |
| Zoetis Completes Acquisition of Nexvet Biopharma
finance.yahoo.com - July 31 at 8:22 AM |
| Zoetis Inc. (NYSE:ZTS) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - July 29 at 4:43 PM |
| Financial Comparison: Zoetis (NYSE:ZTS) & Aratana Therapeutics (PETX)
www.americanbankingnews.com - July 29 at 7:21 AM |
| YieldBoost Zoetis From 0.7% To 2.8% Using Options - Nasdaq
www.nasdaq.com - July 28 at 10:21 AM |
| Zoetis (NYSE:ZTS) versus Aratana Therapeutics (PETX) Critical Survey
www.americanbankingnews.com - July 28 at 8:11 AM |
 | Zoetis Investors May Need Patience To See Bull Thesis Play Out - Benzinga
www.benzinga.com - July 27 at 9:56 AM |
| UPDATE: Deutsche Bank Downgrades Zoetis Inc. (ZTS) to Hold - StreetInsider.com
www.streetinsider.com - July 27 at 9:55 AM |
| UPDATE: Deutsche Bank Downgrades Zoetis Inc. (ZTS) to Hold
www.streetinsider.com - July 26 at 10:45 AM |
| Zoetis, Inc. breached its 50 day moving average in a Bearish Manner : ZTS-US : July 26, 2017
finance.yahoo.com - July 26 at 10:45 AM |
| Zoetis Inc. (NYSE:ZTS) Downgraded by Deutsche Bank AG to "Hold"
www.americanbankingnews.com - July 25 at 10:13 PM |
| Zoetis (NYSE:ZTS) & Aratana Therapeutics (PETX) Financial Review
www.americanbankingnews.com - July 24 at 10:19 PM |
| Zoetis Inc. (NYSE:ZTS) Receives Buy Rating from Stifel Nicolaus
www.americanbankingnews.com - July 21 at 4:52 PM |
| Zoetis Inc. (ZTS) Price Target Increased to $65.00 by Analysts at Deutsche Bank AG
www.americanbankingnews.com - July 17 at 5:58 PM |
| ETFs with exposure to Zoetis, Inc. : July 13, 2017
finance.yahoo.com - July 13 at 8:39 PM |
| Kindred Biosciences: Up 100% YTD With Even Greater Potential In H2
seekingalpha.com - July 13 at 11:35 AM |
| Zoetis Inc. (NYSE:ZTS) Expected to Post Earnings of $0.53 Per Share
www.americanbankingnews.com - July 12 at 10:40 PM |
| Performance of Zoetis Stock in 2Q17
finance.yahoo.com - July 11 at 9:56 AM |
| Zoetis Inc. (ZTS) Expected to Post FY2017 Earnings of $2.26 Per Share
www.americanbankingnews.com - July 6 at 8:00 AM |
| Zoetis Inc. (NYSE:ZTS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 4 at 5:22 PM |
| Zacks Investment Research Lowers Zoetis Inc. (NYSE:ZTS) to Hold
www.americanbankingnews.com - July 4 at 1:04 PM |
| Critical Review: Aratana Therapeutics (PETX) versus Zoetis (ZTS)
www.americanbankingnews.com - July 2 at 4:34 PM |
| Zoetis to Host Webcast and Conference Call on Second Quarter 2017 Financial Results
finance.yahoo.com - July 1 at 9:23 AM |
| ETFs with exposure to Zoetis, Inc. : June 30, 2017
finance.yahoo.com - July 1 at 9:23 AM |
| Phibro Animal Health Corporation (PAHC) vs. Zoetis (ZTS) Critical Review
www.americanbankingnews.com - June 29 at 10:49 AM |
| Cramer's lightning round: Don't go down the food chain in this space
finance.yahoo.com - June 22 at 7:59 PM |
| Hilliard Lyons Reinstates Zoetis Inc. (ZTS) at Buy, "A Top Operator in an Industry with Solid Secular Growth" - StreetInsider.com
www.streetinsider.com - June 22 at 2:57 PM |
| Critical Review: Zoetis (ZTS) and Phibro Animal Health Corporation (PAHC)
www.americanbankingnews.com - June 21 at 10:20 AM |
| Zoetis Inc. (ZTS) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - June 20 at 4:10 PM |
Zoetis (ZTS) Chart for Friday, August, 18, 2017
